文献速递哮喘

重度哮喘生物制剂治疗下的临床缓解:定义问题

Clinical remission with biologic therapies in severe asthma: a matter of definition.
PubMed 文献 · Eur Respir J · 2024-06-20

该文为针对社论的读者来信,讨论重度哮喘生物制剂治疗中临床缓解定义的重要性。作者认同定义需迭代完善,并指出在非呼吸炎症疾病中早期靶向治疗可改善生活质量,重度哮喘领域需前瞻性证据支持早期干预与持续缓解的获益。

要点

  • 临床缓解定义在重度哮喘中至关重要,需迭代完善。
  • 非呼吸炎症疾病中早期靶向治疗可改善生活质量与症状负担。
  • 重度哮喘界需提供早期干预和持续缓解改善结局的前瞻性证据。

核心结论

  • 临床缓解定义对重度哮喘生物制剂治疗至关重要,且定义过程可能需迭代完善。
  • 重度哮喘领域需前瞻性证据证明早期干预和持续缓解可改善生活质量与疾病结局。

主要发现

  • 在风湿病学、胃肠病学和皮肤病学中,早期靶向治疗与生活质量改善和症状负担降低相关。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

There is currently no evidence to support the use of maintenance and reliever therapy (MART) in patients with severe asthma and persistently elevated T2 biomarkers despite adherence to high dose ICS treatment https://bit.ly/42IOVbA We read with interest the editorial “Clinical remission with biologic therapies in severe asthma: a matter of definition” [1]. We absolutely agree that the definition of clinical remission is of critical importance, and as with rheumatology, gastroenterology and dermatology, this is likely to be an iterative process. Early intervention with targeted treatments has been associated with an improvement in quality of life and decreased symptom burden in these non-respiratory inflammatory diseases, and certainly the onus to provide prospective evidence showing improved quality of life and disease outcomes with early intervention and sustained remission in severe asthma now lies with the severe asthma community.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. McDowell PJ, McDowell R, Busby J, et al. Clinical remission with biologic therapies in severe asthma: a matter of definition. Eur Respir J. 2024. PMID: 38901893. doi:10.1183/13993003.00160-2024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。